[EN] INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS [FR] INHIBITEURS DE CATÉCHOL O-MÉTHYL TRANSFÉRASE ET UTILISATION ASSOCIÉE DANS LE TRAITEMENT DE TROUBLES PSYCHOTIQUES
[EN] INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS [FR] INHIBITEURS DE CATÉCHOL O-MÉTHYL TRANSFÉRASE ET UTILISATION ASSOCIÉE DANS LE TRAITEMENT DE TROUBLES PSYCHOTIQUES
INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS
申请人:Wolkenberg Scott
公开号:US20130196002A1
公开(公告)日:2013-08-01
The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.
Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
申请人:Wolkenberg Scott
公开号:US08969364B2
公开(公告)日:2015-03-03
The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.
[EN] INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS<br/>[FR] INHIBITEURS DE CATÉCHOL O-MÉTHYL TRANSFÉRASE ET UTILISATION ASSOCIÉE DANS LE TRAITEMENT DE TROUBLES PSYCHOTIQUES
申请人:MERCK SHARP & DOHME
公开号:WO2011109267A1
公开(公告)日:2011-09-09
The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.